- Capital Cube•26 days ago
Categories: Yahoo Finance Get free summary analysis Eisai Co., Ltd. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Eisai Co., Ltd. – Biogen Inc., Celgene Corporation and AbbVie, Inc. (BIIB-US, CELG-US and ABBV-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD ... Read more (Read more...)
- Zacks•2 months ago
Arena Pharmaceuticals, Inc. (ARNA) announced that it has amended the marketing and supply agreement with Eisai Co., Ltd. (ESALY) for Belviq.
- PR Newswire•2 months agoGerman Institute for Quality and Efficiency in Health Care (IQWiG) Confirms Additional Benefit for Kisplyx® (lenvatinib) in Combination with everolimus for the Treatment of Advanced Renal Cell Carcinoma
HATFIELD, England, January 4, 2017 /PRNewswire/ -- FOR EU MEDIA ONLY: NOT FOR SWISS/ AUSTRIAN MEDIA Approximately 15,000 people in Germany develop renal cell carcinoma every year. The German Institute ...
ESALY : Summary for EISAI CO LTD SPONS A - Yahoo Finance
Eisai Co., Ltd. (ESALY)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||56.01 - 56.39|
|52 Week Range||53.55 - 66.38|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||33.26|
|Dividend & Yield||1.26 (2.25%)|
|1y Target Est||N/A|